Cost-effectiveness of tenofovir instead of zidovudine for use in first-line antiretroviral therapy in settings without virological monitoring

Viktor von Wyl; Valentina Cambiano; Michael R Jordan; Silvia Bertagnolio; Alec Miners; Deenan Pillay; Jens Lundgren; Andrew N Phillips

doi:10.1371/journal.pone.0042834

Cost-effectiveness of tenofovir instead of zidovudine for use in first-line antiretroviral therapy in settings without virological monitoring

Viktor von Wyl, Valentina Cambiano, Michael R Jordan, Silvia Bertagnolio, Alec Miners, Deenan Pillay, Jens Lundgren, Andrew N Phillips

16 Citations (Scopus)

Abstract

The most recent World Health Organization (WHO) antiretroviral treatment guidelines recommend the inclusion of zidovudine (ZDV) or tenofovir (TDF) in first-line therapy. We conducted a cost-effectiveness analysis with emphasis on emerging patterns of drug resistance upon treatment failure and their impact on second-line therapy.

Original language	English
Journal	P L o S One
Volume	7
Issue number	8
Pages (from-to)	e42834
ISSN	1932-6203
DOIs	https://doi.org/10.1371/journal.pone.0042834
Publication status	Published - 2012

Access to Document

10.1371/journal.pone.0042834

Cite this

@article{fb5917cd80a94701aba89080802dbd21,

title = "Cost-effectiveness of tenofovir instead of zidovudine for use in first-line antiretroviral therapy in settings without virological monitoring",

abstract = "The most recent World Health Organization (WHO) antiretroviral treatment guidelines recommend the inclusion of zidovudine (ZDV) or tenofovir (TDF) in first-line therapy. We conducted a cost-effectiveness analysis with emphasis on emerging patterns of drug resistance upon treatment failure and their impact on second-line therapy.",

author = "\{von Wyl\}, Viktor and Valentina Cambiano and Jordan, \{Michael R\} and Silvia Bertagnolio and Alec Miners and Deenan Pillay and Jens Lundgren and Phillips, \{Andrew N\}",

year = "2012",

doi = "10.1371/journal.pone.0042834",

language = "English",

volume = "7",

pages = "e42834",

journal = "P L o S One",

issn = "1932-6203",

publisher = "Public Library of Science",

number = "8",

}

TY - JOUR

T1 - Cost-effectiveness of tenofovir instead of zidovudine for use in first-line antiretroviral therapy in settings without virological monitoring

AU - von Wyl, Viktor

AU - Cambiano, Valentina

AU - Jordan, Michael R

AU - Bertagnolio, Silvia

AU - Miners, Alec

AU - Pillay, Deenan

AU - Lundgren, Jens

AU - Phillips, Andrew N

PY - 2012

Y1 - 2012

N2 - The most recent World Health Organization (WHO) antiretroviral treatment guidelines recommend the inclusion of zidovudine (ZDV) or tenofovir (TDF) in first-line therapy. We conducted a cost-effectiveness analysis with emphasis on emerging patterns of drug resistance upon treatment failure and their impact on second-line therapy.

AB - The most recent World Health Organization (WHO) antiretroviral treatment guidelines recommend the inclusion of zidovudine (ZDV) or tenofovir (TDF) in first-line therapy. We conducted a cost-effectiveness analysis with emphasis on emerging patterns of drug resistance upon treatment failure and their impact on second-line therapy.

UR - https://www.scopus.com/pages/publications/84864657774

U2 - 10.1371/journal.pone.0042834

DO - 10.1371/journal.pone.0042834

M3 - Journal article

C2 - 22905175

SN - 1932-6203

VL - 7

SP - e42834

JO - P L o S One

JF - P L o S One

IS - 8

ER -

Cost-effectiveness of tenofovir instead of zidovudine for use in first-line antiretroviral therapy in settings without virological monitoring

Abstract

Access to Document

Other files and links

Fingerprint

Cite this